Halozyme Therapeutics (NASDAQ:HALO) Stock Price Target Raised at Wells Fargo & Company

Halozyme Therapeutics (NASDAQ:HALO) had its price objective hoisted by equities researchers at Wells Fargo & Company from $95.00 to $110.00 in a research note issued to investors on Friday, Benzinga reports. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price target would suggest a potential downside of 4.59% from the company’s current price.

A number of other research analysts have also issued reports on the stock. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Citizens Jmp raised their price target on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a research note on Friday, August 7th. Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and raised their price target for the company from $83.00 to $110.00 in a research note on Friday, August 7th. TD Cowen lifted their price target on Halozyme Therapeutics from $105.00 to $130.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. Finally, Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $101.00.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $115.29 on Friday. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The firm has a market capitalization of $13.09 billion, a PE ratio of 34.55, a P/E/G ratio of 0.49 and a beta of 0.92. Halozyme Therapeutics has a 1-year low of $61.22 and a 1-year high of $134.00. The business’s fifty day moving average price is $115.26 and its two-hundred day moving average price is $84.57.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.09. The company had revenue of $492.97 million during the quarter, compared to the consensus estimate of $491.63 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company’s revenue for the quarter was up 39.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.72 earnings per share. On average, research analysts expect that Halozyme Therapeutics will post 8.32 EPS for the current year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $109.40, for a total transaction of $2,188,000.00. Following the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $83,995,132. The trade was a 2.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the sale, the director directly owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. This represents a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 125,852 shares of company stock worth $13,538,046. 2.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Hilton Head Capital Partners LLC acquired a new stake in Halozyme Therapeutics in the third quarter valued at approximately $33,000. CoreCap Advisors LLC grew its position in Halozyme Therapeutics by 98.0% in the third quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 150 shares in the last quarter. MidFirst Bank bought a new stake in Halozyme Therapeutics in the second quarter worth approximately $27,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter worth $28,000. Finally, Quantbot Technologies LP acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter worth $30,000. 97.79% of the stock is owned by institutional investors.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Revenue rose 39% year over year to a record $493 million, while royalty revenue climbed 44% to $341 million. Adjusted diluted EPS of $2.39 also topped analyst expectations of about $2.30. Halozyme Q3 results and guidance
• Positive Sentiment: Halozyme raised its 2026 guidance, projecting revenue of $1.86 billion–$1.925 billion, royalty revenue of $1.235 billion–$1.255 billion, adjusted EBITDA of $1.24 billion–$1.29 billion, and non-GAAP EPS of $8.75–$9.05. Higher guidance points to stronger expected growth and earnings. Halozyme Q3 results and guidance
• Positive Sentiment: The company expanded ENHANZE collaboration agreements with three existing partners, and three ENHANZE programs advanced into Phase 1 clinical development, adding to potential future royalty opportunities. Halozyme Q3 results and guidance
• Negative Sentiment: Despite the earnings beat and raised outlook, reports said HALO shares fell after the results. The supplied coverage does not identify a specific reason; the reaction may reflect investor expectations or profit-taking rather than weakness in the reported quarter. Halozyme Q3 stock reaction

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.